TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kalimanovska-Oštrić, Dimitra
AU  - Andelković, Kristina
AU  - Jelić-Ivanović, Zorana
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2817
AB  - BackgroundAdenylate cyclase-associated protein 1 (CAP1) is a recently identified receptor for human resistin. As resistin has been related to CAD development and progression and CAP1 has never been evaluated in CAD, the aim of this study was to determine its peripheral blood mononuclear cells (PBMCs) mRNA in patients with CAD, and resistin plasma concentration, PBMCs resistin and CD36 mRNA, considering resistis ability to stimulate CD36 expression invitro. Materials and methodsThis case-controlled study included 27 healthy subjects (CG) and 66 patients requiring coronary angiography. Of the latter, 42 had nonsignificant CAD whereas 24 had significant CAD. Circulating resistin was measured by ELISA; PBMCs CAP1, resistin and CD36 mRNA were determined by real-time PCR. ResultsPatients with significant as well as patients with nonsignificant CAD had significantly higher resistin concentrations compared to the CG (P lt 0 lt bold> lt /bold>001; P=0 lt bold> lt /bold>003). Resistin mRNA did not show significant difference between the investigated groups. CAP1 and CD36 mRNA were significantly higher in significant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) and nonsignificant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) compared to the CG; significant CAD showed significantly higher CD36 mRNA (P=0 lt bold> lt /bold>040) compared to the nonsignificant CAD group. Multiple linear regression analysis identified Tg and CD36 mRNA as independent predictors of CAP1 (R-2=0 lt bold> lt /bold>402; adjR(2)=0 lt bold> lt /bold>376). ConclusionSignificant up-regulation of PBMCs CAP1, CD36 mRNA and plasma resistin found in significant CAD, as well as in nonsignificant CAD compared to CG, indicates that resistin could be able to exert its effects stronger on cells with up-regulated CAP1 mRNA thus contributing atherosclerosis development.
PB  - Wiley, Hoboken
T2  - European Journal of Clinical Investigation
T1  - Association of adenylate cyclase-associated protein 1 with coronary artery disease
VL  - 47
IS  - 9
SP  - 659
EP  - 666
DO  - 10.1111/eci.12787
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Spasojević-Kalimanovska, Vesna and Kalimanovska-Oštrić, Dimitra and Andelković, Kristina and Jelić-Ivanović, Zorana",
year = "2017",
abstract = "BackgroundAdenylate cyclase-associated protein 1 (CAP1) is a recently identified receptor for human resistin. As resistin has been related to CAD development and progression and CAP1 has never been evaluated in CAD, the aim of this study was to determine its peripheral blood mononuclear cells (PBMCs) mRNA in patients with CAD, and resistin plasma concentration, PBMCs resistin and CD36 mRNA, considering resistis ability to stimulate CD36 expression invitro. Materials and methodsThis case-controlled study included 27 healthy subjects (CG) and 66 patients requiring coronary angiography. Of the latter, 42 had nonsignificant CAD whereas 24 had significant CAD. Circulating resistin was measured by ELISA; PBMCs CAP1, resistin and CD36 mRNA were determined by real-time PCR. ResultsPatients with significant as well as patients with nonsignificant CAD had significantly higher resistin concentrations compared to the CG (P lt 0 lt bold> lt /bold>001; P=0 lt bold> lt /bold>003). Resistin mRNA did not show significant difference between the investigated groups. CAP1 and CD36 mRNA were significantly higher in significant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) and nonsignificant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) compared to the CG; significant CAD showed significantly higher CD36 mRNA (P=0 lt bold> lt /bold>040) compared to the nonsignificant CAD group. Multiple linear regression analysis identified Tg and CD36 mRNA as independent predictors of CAP1 (R-2=0 lt bold> lt /bold>402; adjR(2)=0 lt bold> lt /bold>376). ConclusionSignificant up-regulation of PBMCs CAP1, CD36 mRNA and plasma resistin found in significant CAD, as well as in nonsignificant CAD compared to CG, indicates that resistin could be able to exert its effects stronger on cells with up-regulated CAP1 mRNA thus contributing atherosclerosis development.",
publisher = "Wiley, Hoboken",
journal = "European Journal of Clinical Investigation",
title = "Association of adenylate cyclase-associated protein 1 with coronary artery disease",
volume = "47",
number = "9",
pages = "659-666",
doi = "10.1111/eci.12787"
}

Munjas, J., Sopić, M., Spasojević-Kalimanovska, V., Kalimanovska-Oštrić, D., Andelković, K.,& Jelić-Ivanović, Z.. (2017). Association of adenylate cyclase-associated protein 1 with coronary artery disease. in European Journal of Clinical Investigation
Wiley, Hoboken., 47(9), 659-666.
https://doi.org/10.1111/eci.12787

Munjas J, Sopić M, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Andelković K, Jelić-Ivanović Z. Association of adenylate cyclase-associated protein 1 with coronary artery disease. in European Journal of Clinical Investigation. 2017;47(9):659-666.
doi:10.1111/eci.12787 .

Munjas, Jelena, Sopić, Miron, Spasojević-Kalimanovska, Vesna, Kalimanovska-Oštrić, Dimitra, Andelković, Kristina, Jelić-Ivanović, Zorana, "Association of adenylate cyclase-associated protein 1 with coronary artery disease" in European Journal of Clinical Investigation, 47, no. 9 (2017):659-666,
https://doi.org/10.1111/eci.12787 . .

TY  - CONF
AU  - Sopić, Miron
AU  - Joksić, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kalimanovska-Oštrić, Dimitra
AU  - Andelković, Kristina
AU  - Jelić-Ivanović, Zorana
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2646
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with coronary artery disease
VL  - 252
SP  - e246
EP  - e247
DO  - 10.1016/j.atherosclerosis.2016.07.046
ER  - 

@conference{
author = "Sopić, Miron and Joksić, Jelena and Spasojević-Kalimanovska, Vesna and Kalimanovska-Oštrić, Dimitra and Andelković, Kristina and Jelić-Ivanović, Zorana",
year = "2016",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with coronary artery disease",
volume = "252",
pages = "e246-e247",
doi = "10.1016/j.atherosclerosis.2016.07.046"
}

Sopić, M., Joksić, J., Spasojević-Kalimanovska, V., Kalimanovska-Oštrić, D., Andelković, K.,& Jelić-Ivanović, Z.. (2016). Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with coronary artery disease. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 252, e246-e247.
https://doi.org/10.1016/j.atherosclerosis.2016.07.046

Sopić M, Joksić J, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Andelković K, Jelić-Ivanović Z. Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with coronary artery disease. in Atherosclerosis. 2016;252:e246-e247.
doi:10.1016/j.atherosclerosis.2016.07.046 .

Sopić, Miron, Joksić, Jelena, Spasojević-Kalimanovska, Vesna, Kalimanovska-Oštrić, Dimitra, Andelković, Kristina, Jelić-Ivanović, Zorana, "Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with coronary artery disease" in Atherosclerosis, 252 (2016):e246-e247,
https://doi.org/10.1016/j.atherosclerosis.2016.07.046 . .

TY  - JOUR
AU  - Sopić, Miron
AU  - Joksić, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kalimanovska-Oštrić, Dimitra
AU  - Andelković, Kristina
AU  - Jelić-Ivanović, Zorana
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2417
AB  - The aim of the present study was to investigate if circulating adiponectin levels and the expression of AdipoR1 and AdipoR2 in peripheral blood mononuclear cells (PBMC) are altered in coronary artery disease (CAD) patients, with and without significant stenosis, compared to healthy patients. The present study included 69 patients with presenting symptoms of CAD (26 patients with significant stenosis and 43 patients without significant stenosis). The control group (CG) consisted of 33 healthy patients. Circulating adiponectin levels were measured by enzyme-linked immunosorbent assay, whereas AdipoR1 and AdipoR2 mRNA levels in PBMC were determined by real-time polymerase chain reaction. Adiponectin levels were significantly higher in patients with and without significant stenosis compared to the CG (P lt 0.001 vs P=0.006, respectively). Both patient groups had lower AdipoR1 levels compared to the CG (P lt 0.001 vs P lt 0.001, respectively). There were no significant differences in these parameters between the two patient groups. Adiponectin negatively correlated with body mass index, triglycerides, insulin and homeostasis model assessment of insulin resistance index (HOMA IR), and positively with high-denisty lipoprotein cholesterol in the CG. Glucose, insulin, and the HOMA IR index negatively correlated with adiponectin in patients. A positive correlation between adiponectin receptors was found in patients and the CG. Decreased AdipoR1 mRNA levels and increased circulating adiponectin in advanced stages of CAD, as well as in patients without significant stenosis, compared to the CG, implies that CAD could be related to adiponectin resistance'. Despite increased adiponectin, its protective effects could be diminished even in early stages of atherosclerosis.
PB  - Wiley, Hoboken
T2  - Clinical and Experimental Pharmacology and Physiology
T1  - Are decreased AdipoR1 mRNA levels associated with adiponectin resistance in coronary artery disease patients?
VL  - 42
IS  - 4
SP  - 331
EP  - 336
DO  - 10.1111/1440-1681.12361
ER  - 

@article{
author = "Sopić, Miron and Joksić, Jelena and Spasojević-Kalimanovska, Vesna and Kalimanovska-Oštrić, Dimitra and Andelković, Kristina and Jelić-Ivanović, Zorana",
year = "2015",
abstract = "The aim of the present study was to investigate if circulating adiponectin levels and the expression of AdipoR1 and AdipoR2 in peripheral blood mononuclear cells (PBMC) are altered in coronary artery disease (CAD) patients, with and without significant stenosis, compared to healthy patients. The present study included 69 patients with presenting symptoms of CAD (26 patients with significant stenosis and 43 patients without significant stenosis). The control group (CG) consisted of 33 healthy patients. Circulating adiponectin levels were measured by enzyme-linked immunosorbent assay, whereas AdipoR1 and AdipoR2 mRNA levels in PBMC were determined by real-time polymerase chain reaction. Adiponectin levels were significantly higher in patients with and without significant stenosis compared to the CG (P lt 0.001 vs P=0.006, respectively). Both patient groups had lower AdipoR1 levels compared to the CG (P lt 0.001 vs P lt 0.001, respectively). There were no significant differences in these parameters between the two patient groups. Adiponectin negatively correlated with body mass index, triglycerides, insulin and homeostasis model assessment of insulin resistance index (HOMA IR), and positively with high-denisty lipoprotein cholesterol in the CG. Glucose, insulin, and the HOMA IR index negatively correlated with adiponectin in patients. A positive correlation between adiponectin receptors was found in patients and the CG. Decreased AdipoR1 mRNA levels and increased circulating adiponectin in advanced stages of CAD, as well as in patients without significant stenosis, compared to the CG, implies that CAD could be related to adiponectin resistance'. Despite increased adiponectin, its protective effects could be diminished even in early stages of atherosclerosis.",
publisher = "Wiley, Hoboken",
journal = "Clinical and Experimental Pharmacology and Physiology",
title = "Are decreased AdipoR1 mRNA levels associated with adiponectin resistance in coronary artery disease patients?",
volume = "42",
number = "4",
pages = "331-336",
doi = "10.1111/1440-1681.12361"
}

Sopić, M., Joksić, J., Spasojević-Kalimanovska, V., Kalimanovska-Oštrić, D., Andelković, K.,& Jelić-Ivanović, Z.. (2015). Are decreased AdipoR1 mRNA levels associated with adiponectin resistance in coronary artery disease patients?. in Clinical and Experimental Pharmacology and Physiology
Wiley, Hoboken., 42(4), 331-336.
https://doi.org/10.1111/1440-1681.12361

Sopić M, Joksić J, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Andelković K, Jelić-Ivanović Z. Are decreased AdipoR1 mRNA levels associated with adiponectin resistance in coronary artery disease patients?. in Clinical and Experimental Pharmacology and Physiology. 2015;42(4):331-336.
doi:10.1111/1440-1681.12361 .

Sopić, Miron, Joksić, Jelena, Spasojević-Kalimanovska, Vesna, Kalimanovska-Oštrić, Dimitra, Andelković, Kristina, Jelić-Ivanović, Zorana, "Are decreased AdipoR1 mRNA levels associated with adiponectin resistance in coronary artery disease patients?" in Clinical and Experimental Pharmacology and Physiology, 42, no. 4 (2015):331-336,
https://doi.org/10.1111/1440-1681.12361 . .